News
HOPHF
0.040
NaN%
--
Hemogenyx signs LOI to explore CAR-T therapy commercialization in Estonia
Seeking Alpha · 09/23/2025 06:47
Weekly Report: what happened at HOPHF last week (0908-0912)?
Weekly Report · 09/15/2025 11:33
Weekly Report: what happened at HOPHF last week (0901-0905)?
Weekly Report · 09/08/2025 11:36
Hemogenyx Pharmaceuticals to issue convertible loan notes
Seeking Alpha · 09/02/2025 08:03
Weekly Report: what happened at HOPHF last week (0825-0829)?
Weekly Report · 09/01/2025 11:30
Weekly Report: what happened at HOPHF last week (0818-0822)?
Weekly Report · 08/25/2025 11:43
Weekly Report: what happened at HOPHF last week (0811-0815)?
Weekly Report · 08/18/2025 11:33
Hemogenyx Pharmaceuticals PLC - Third Patient Treated with HG-CT-1 CAR-T Therapy
Barchart · 08/14/2025 21:00
Weekly Report: what happened at HOPHF last week (0804-0808)?
Weekly Report · 08/11/2025 11:42
Weekly Report: what happened at HOPHF last week (0728-0801)?
Weekly Report · 08/04/2025 11:45
Weekly Report: what happened at HOPHF last week (0721-0725)?
Weekly Report · 07/28/2025 11:45
Weekly Report: what happened at HOPHF last week (0714-0718)?
Weekly Report · 07/21/2025 11:34
Weekly Report: what happened at HOPHF last week (0707-0711)?
Weekly Report · 07/14/2025 11:45
Weekly Report: what happened at HOPHF last week (0630-0704)?
Weekly Report · 07/07/2025 11:35
Weekly Report: what happened at HOPHF last week (0623-0627)?
Weekly Report · 06/30/2025 11:42
Weekly Report: what happened at HOPHF last week (0616-0620)?
Weekly Report · 06/23/2025 11:33
Weekly Report: what happened at HOPHF last week (0609-0613)?
Weekly Report · 06/16/2025 11:42
More
Webull provides a variety of real-time HOPHF stock news. You can receive the latest news about Hemogenyx Pharma through multiple platforms. This information may help you make smarter investment decisions.
About HOPHF
Hemogenyx Pharmaceuticals plc is a clinical-stage biotechnology company. The Company is engaged in the discovery, development and commercialization of a suite of products to address problems associated with the treatment of blood disorders, such as cancers and autoimmune diseases, and viral infections. Its products include immunotherapy product candidates for the treatment of acute myeloid leukemia (AML) and other blood malignancies and patient conditioning for bone marrow transplantation (the CDX bi-specific antibody and CAR-T therapy), and a cell therapy product for BM/HSC transplantation (the Hu-PHEC). Its lead product, HG-CT-1, is a CAR-T cell therapy designed to treat relapsed or refractory acute myeloid leukemia (R/R AML), which is in a Phase I clinical trial. Its Chimeric Bait Receptor (CBR) is a versatile range of potential treatments based on the methodology of programming immune cells using a type of modifiable synthetic receptor to destroy viral pathogens.